US6743774B1ExpiredUtility
Tribonectins
Est. expiryApr 23, 2019(expired)· nominal 20-yr term from priority
Inventors:Gregory D. Jay
A61P 43/00A61P 41/00A61P 9/00A61K 38/00A61P 19/02A61K 38/1709A61P 17/02C07K 14/47A61K 48/00A61P 19/10C07K 14/475
90
PatentIndex Score
56
Cited by
35
References
26
Claims
Abstract
The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A method of lubricating a mammalian joint, comprising contacting said joint with a purified polypeptide comprising residues 200-1140 of SEQ ID NO:1 and an O-linked oligosaccharide.
2. The method of claim 1 , wherein said joint is an articulating joint of a human.
3. The method of claim 1 , wherein said joint is an articulating joint of a dog.
4. The method of claim 1 , wherein said joint is an articulating joint of a horse.
5. The method of claim 1 , wherein said tribonectin is administered intra-articularly.
6. A method of inhibiting adhesion formation between a first surface and a second surface in a mammal, said method comprising placing a tribonectin between said first and second surfaces in an amount sufficient to prevent adhesion of said surfaces in said mammal, wherein said tribonectin is a purified polypeptide comprising residues 200-1140 of SEQ ID NO:1 and an O-linked oligosaccharide.
7. The method of claim 6 , wherein said first surface and said second surface are both injured tissues of said mammal.
8. The method of claim 6 , wherein said first or said second surface is an artificial device.
9. The method of claim 8 , wherein said artificial device is an orthopedic implant.
10. The method of claim 6 , wherein said tribonectin is present in a composition, said composition being in the form of a membrane, foam, gel, or fiber.
11. The method of claim 6 , wherein said first and said second surfaces are tissues injured due to a surgical incision.
12. The method of claim 6 , wherein said first and said second surfaces are tissues injured due to trauma.
13. A method of lubricating a mammalian joint, comprising contacting said joint with a purified tribonectin, wherein said tribonectin is a fragment of megakaryocyte stimulating factor (MSF) comprising residues 200-1140 of SEQ ID NO: 1, wherein said fragment comprises an O-linked oligosaccharide.
14. The method of claim 13 , wherein said tribonectin further comprises residues 1141-1167 of SEQ ID NO:1.
15. The method of claim 14 , wherein said tribonectin further comprises residues 1168-1212 of SEQ ID NO: 1.
16. The method of claim 15 , wherein said tribonectin further comprises residues 1213-1263 of SEQ ID NO: 1.
17. The method of claim 13 , wherein said tribonectin comprises residues 200-1263 of SEQ ID NO: 1.
18. The method of claim 1 , wherein said polypeptide is recombinant.
19. The method of claim 6 , wherein said polypeptide is recombinant.
20. The method of claim 1 , wherein said polypeptide is chemically synthesized.
21. The method of claim 6 , wherein said polypeptide is chemically synthesized.
22. The method of claim 1 , 6 , or 13 , wherein said O-linked oligosaccharide is β(1,3)Gal-GalNAC.
23. The method of claim 1 , 6 , or 13 , wherein said O-linked oligosaccharide is β(1,3)Gal-GalNeuAc.
24. A method of lubricating a mammalian joint, comprising contacting said joint with a purified polypeptide comprising an amino acid sequence in which at least one threonine in the amino acid sequence of residues 200-1140 of SEQ ID NO:1 is substituted with a serine, wherein said polypeptide is glycosylated.
25. The method of claim 24 , wherein said polypeptide comprises an O-linked oligosaccharide.
26. A method of lubricating a mammalian joint, comprising contacting said joint with a purified tribonectin, wherein said tribonectin is an alternatively spliced variant of human megakaryocyte stimulating factor (MSF) gene, wherein said variant comprises at least an O-glycosylated mucin domain, wherein said mucin domain is encoded by exon 6 of a human MSF gene.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.